Your browser doesn't support javascript.
loading
Mesenchymal Stem Cells Delivery in Individuals with Different Pathologies: Multimodal Tracking, Safety and Future Applications.
Belmar-López, Carolina; Vassaux, Georges; Medel-Martinez, Ana; Burnet, Jerome; Quintanilla, Miguel; Ramón Y Cajal, Santiago; Hernandez-Losa, Javier; De la Vieja, Antonio; Martin-Duque, Pilar.
Affiliation
  • Belmar-López C; Instituto Aragonés de Ciencias de la Salud/IIS Aragón, 50009 Zaragoza, Spain.
  • Vassaux G; Institut de Pharmacologie Moléculaire et Cellulaire, INSERM, CNRS, Université Côte d'Azur, 06560 Valbonne, France.
  • Medel-Martinez A; Instituto Aragonés de Ciencias de la Salud/IIS Aragón, 50009 Zaragoza, Spain.
  • Burnet J; Cancer Research UK, Queen Mary University of London, London E1 4NS, UK.
  • Quintanilla M; Instituto de Investigaciones Biomedicas Alberto Sols (CSIC-UAM), 28029 Madrid, Spain.
  • Ramón Y Cajal S; Pathology Department, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain.
  • Hernandez-Losa J; Pathology Department, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain.
  • De la Vieja A; Endocrine Tumors Unit, Unidad Funcional de Investigación en Enfermedades Endocrinas (UFIEC), Instituto de Salud Carlos III (ISCIII), 28222 Majadahonda, Spain.
  • Martin-Duque P; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain.
Int J Mol Sci ; 23(3)2022 Jan 31.
Article in En | MEDLINE | ID: mdl-35163605
ABSTRACT
Due to their ease of isolation and their properties, mesenchymal stem cells (MSCs) have been widely investigated. MSCs have been proved capable of migration towards areas of inflammation, including tumors. Therefore, they have been suggested as vectors to carry therapies, specifically to neoplasias. As most of the individuals joining clinical trials that use MSCs for cancer and other pathologies are carefully recruited and do not suffer from other diseases, here we decided to study the safety and application of iv-injected MSCs in animals simultaneously induced with different inflammatory pathologies (diabetes, wound healing and tumors). We studied this by in vitro and in vivo approaches using different gene reporters (GFP, hNIS, and f-Luc) and non-invasive techniques (PET, BLI, or fluorescence). Our results found that MSCs reached different organs depending on the previously induced pathology. Moreover, we evaluated the property of MSCs to target tumors as vectors to deliver adenoviruses, including the interaction between tumor microenvironment and MSCs on their arrival. Mechanisms such as transdifferentiation, MSC fusion with cells, or paracrine processes after MSCs homing were studied, increasing the knowledge and safety of this new therapy for cancer.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Mesenchymal Stem Cell Transplantation / Tumor Microenvironment / Mesenchymal Stem Cells / Neoplasms Limits: Animals / Female / Humans Language: En Journal: Int J Mol Sci Year: 2022 Type: Article Affiliation country: Spain

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Mesenchymal Stem Cell Transplantation / Tumor Microenvironment / Mesenchymal Stem Cells / Neoplasms Limits: Animals / Female / Humans Language: En Journal: Int J Mol Sci Year: 2022 Type: Article Affiliation country: Spain